With coronavirus cases around the world now at over 56 million, scientists have been working around the clock to develop a vaccine.
A jab developed at the University of Oxford has been tipped as the front-runner, with results showing the effectiveness expected in the coming week.
Promising Phase II trial data released today suggests the jab produces a strong immune response in older adults. Dr Maheshi Ramasamy, investigator at the Oxford Vaccine Group and consultant physician, said: "Older adults are a priority group for Covid-19 vaccination, because they are at increased risk of severe disease, but we know that they tend to have poorer vaccine responses. "We were pleased to see that our vaccine was not only well tolerated in older adults,